The global demand for Branded Generics Market is presumed to reach the market size of nearly USD XX MN by 2030 from USD XX MN in 2022 with a CAGR of XX% under the study period 2023 - 2030.
Branded generics refer to generic drugs that have been provided with a market name. They are generally marketed akin to the way branded drugs are. In comparison, ordinary generic drugs are usually known by their chemical names. However, branded generics are advantageous as they promote consumer loyalty and drive recognition. Some branded generics are also made particularly as novel dosage forms of off-patent drugs. Filling in a dosage gap while simultaneously providing consumers a name that is easy to remember than the true generic name is the most significant advantage of branded generics.
Market Dynamics
Branded generics have several advantages, including manufacturers' ability to get name recognition and higher costs than ordinary generics. They are a cheaper alternative to branded drugs and often work towards releasing savings. Further, the product is slowly gaining popularity due to efficacy, trusted quality, and differentiated products. They are showing growth in low-and middle-income countries like China, India, Chile, etc. as well and are currently considered a small but profitable subset of the whole generic market. However, it needs to be noted that if they are not co-formulated, higher pill burdens may discourage adherence. Further, the problem with the product is that their appearance can at times change if the pharmacy producing the medicine changes as well. This can confuse consumers.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of branded generics. The growth and trends of branded generics industry provide a holistic approach to this study.
Market Segmentation
This section of the branded generics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Therapeutic Application
- Oncology
- Cardiovascular Diseases
- Diabetes
- Neurology
- Gastrointestinal Diseases
- Dermatology Diseases
- Analgesics And Anti-Inflammatory
- Others
By Drug Class
- Alkylating Agents
- Antimetabolites
- Hormones
- Anti-Hypertensive
- Lipid Lowering Drugs
- Anti-Depressants
- Anti-Psychotics
- Anti-Epileptics
- Others
By Formulation Type
- Oral
- Parenteral
- Topical
- Others
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Drug Stores
Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Branded Generics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
Global Branded Generics Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the branded generics market include Teva, Viatris, Novartis (Sandoz), Apotex Inc., Sun Pharmaceutical Industries Ltd, Fresenius Medical Care, Aurobindo Pharma, Lupin, Aspen Pharma, Amneal Pharmaceuticals, Inc, Others. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.